

FORM D

Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992

Regulations 13(4), 13(4A) and 13(6)


Details of change in shareholding or voting rights held by Director or Officer and his dependents or Promoter or Person who is part of Promoter Group of a listed company.


Name, PAN No. & Address of Promoter/ Person who is part of Promoter Group/Director/Officer.	No. & % of shares/ voting rights held by the Promoter/ Person who is part of Promoter Group/Director/Officer.	Date of receipt of allotment advice/ acquisition/ sale of shares/ voting rights	Date of intimation to company	Mode of acquisition (market purchase/ public rights/ preferential offer, etc.)/ sale	No. & % of shares/ voting rights post acquisition / sale	Trading member through whom the trade was executed with SEBI Registration No. of the TM	Exchange on which the trade was executed	Buy quantity	Buy value	Sell quantity	Sell value (INR)
Novartis AG, PAN: AAACN4932F Address: Lichtstrasse 35 4056 Basel Switzerland	24,424,802 (76.42%)	30 May, 2013	31 May, 2013	Market sale through the Offer for Sale mechanism as per SEBI circular number CIR/MRD/DP/18/2012 dated 18 July, 2012, as amended from time to time	23,970,597 (75.00%)	Citigroup Global Markets India Private Limited (SEBI Registration No. INB011141331)	BSE	NA	NA	454,205	254,495,854.50

Place: Basel

Date: 31 May, 2013

For Novartis AG


Jena-Baptiste Emery
Authorized Signatory


Martin Morawietz
Authorized Signatory